Rodríguez-Varela Cristina, Salvaleda-Mateu Maria, Bosch Ernesto, Labarta Elena
Global Research Alliance - IVI Foundation (IIS La Fe). Research Department, Avinguda de Fernando Abril Martorell, 106. 46026, Valencia, Spain.
Global Research Alliance - IVI RMA Valencia. Human Reproduction Department, Plaza Policía Local, 3, 46015, Valencia, Spain.
Reprod Sci. 2025 Feb;32(2):488-494. doi: 10.1007/s43032-024-01759-6. Epub 2024 Dec 23.
To elucidate if morning or evening start of exogenous progesterone (P4) five days before blastocyst embryo transfer (ET) impacts ongoing pregnancy rates (OPR) in artificial cycles.
Single-centre retrospective cohort study of 6493 artificial cycles for an ET (oestrogens and luteal phase support [LPS] with micronized vaginal progesterone [MVP] 400 mg/12 h), conducted at an infertility clinic, December 2018-July 2022. LPS was given from five days before ET. Until March 2021, LPS was started in the evening of day 0 of P4 exposure ("evening start"); since April 2021, LPS was started in the morning of day 0 ("morning start").
Morning start of LPS (n = 2482 cycles); evening start (n = 3983 cycles). Morning or evening start did not exert any impact in OPR (46.9% vs. 46.3%, p = 0.682), as well as after adjusting for any potential confounders (aOR (95%CI): 1.00 (0.89-1.13); p = 0.996). Regarding serum P4 levels, no differences were found between morning (13.4 ± 5.8 ng/ml) and evening start of LPS (13.2 ± 6.4 ng/ml; p = 0.181). However, suboptimal serum P4 levels on the ET day (< 8.8 ng/ml) were registered in 16.6% (n = 411) vs. 19.8% (n = 788) of cycles with a morning and evening start, respectively (p = 0.001).
A 12-h difference in exogenous P4 initiation does not exert an impact on pregnancy outcomes in artificial cycles with MVP, as far as it is started five days before ET. Results from this study offer a great advantage in patient management, by being able to start LPS either in the morning or in the evening five days before blastocyst transfer.
阐明在囊胚胚胎移植(ET)前五天开始外源性孕酮(P4)的时间是早晨还是晚上对人工周期中的持续妊娠率(OPR)有无影响。
对2018年12月至2022年7月在一家不孕症诊所进行的6493个ET人工周期(使用雌激素和黄体期支持[LPS],联合微粒化阴道孕酮[MVP]400mg/12小时)进行单中心回顾性队列研究。LPS在ET前五天开始使用。直到2021年3月,LPS在P4暴露第0天的晚上开始(“晚上开始”);自2021年4月起,LPS在第0天的早晨开始(“早晨开始”)。
LPS早晨开始(n = 2482个周期);晚上开始(n = 3983个周期)。早晨或晚上开始对OPR没有任何影响(46.9%对46.3%,p = 0.682),在调整任何潜在混杂因素后也是如此(调整后的比值比[aOR,95%置信区间]:1.00[0.89 - 1.13];p = 0.996)。关于血清P4水平,LPS早晨开始(13.4±5.8ng/ml)和晚上开始(13.2±6.4ng/ml;p = 0.181)之间没有差异。然而,ET当天血清P4水平未达最佳(<8.8ng/ml)的情况在早晨开始的周期中占16.6%(n = 411),而在晚上开始的周期中占19.8%(n = 788)(p = 0.001)。
在外源性P4开始使用时间上相差12小时,只要是在ET前五天开始,对使用MVP的人工周期妊娠结局没有影响。本研究结果在患者管理方面具有很大优势,因为在囊胚移植前五天可以在早晨或晚上开始使用LPS。